Expand APRE Menu
APRE MENU

APRE Latest Press Releases

-- February 12, 2026 --

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth Globe Newswire 8:30 AM

-- February 4, 2026 --

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor Globe Newswire 8:30 AM

-- January 29, 2026 --

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan Globe Newswire 8:27 AM
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules Globe Newswire 8:25 AM

-- December 23, 2025 --

Holiday Gifts: HXHX, BMXI, ABQQ, TOON, PRSO Stocks Under $1 See More Inside Now! AB Digital Inc 12:57 PM

-- December 18, 2025 --

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 Globe Newswire 8:30 AM

-- December 11, 2025 --

Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL - Stocks Under $1 Look Now AB Digital Inc 3:06 PM

-- December 9, 2025 --

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules Globe Newswire 8:30 AM

-- December 3, 2025 --

$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside AB Digital Inc 3:14 PM

-- November 25, 2025 --

Datavault AI (NASDAQ: DVLT) Bullish Signals Trigger Strong Upside - Similar Patterns Seen in PRSO, SNYR, TOON more inside. AB Digital Inc 3:18 PM

-- November 18, 2025 --

Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target AB Digital Inc 3:47 PM

-- November 12, 2025 --

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update Globe Newswire 8:30 AM

-- October 24, 2025 --

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 Globe Newswire 8:30 AM

-- October 15, 2025 --

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies Globe Newswire 8:00 AM

-- October 14, 2025 --

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes